ABSTRACT-Microparticles are submicron vesicles shed from aging erythrocytes as a characteristic feature of the red blood cell (RBC) storage lesion. Exposure of pulmonary endothelial cells to RBC-derived microparticles promotes an inflammatory response, but the mechanisms underlying microparticle-induced endothelial cell activation are poorly understood. In the present study, cultured murine lung endothelial cells (MLECs) were treated with microparticles isolated from aged murine packed RBCs or vehicle. Microparticle-treated cells demonstrated increased expression of the adhesion molecules ICAM and E-selectin, as well as the cytokine, IL-6. To identify mechanisms that mediate these effects of microparticles on MLECs, cells were treated with microparticles covalently bound to carboxyfluorescein succinimidyl ester (CFSE) and cellular uptake of microparticles was quantified via flow cytometry. Compared with controls, there was a greater proportion of CFSE-positive MLECs from 15 min up to 24 h, suggesting endocytosis of the microparticles by endothelial cells. Colocalization of microparticles with lysosomes was observed via immunofluorescence, indicating endocytosis and endolysosomal trafficking. This process was inhibited by endocytosis inhibitors. SiRNA knockdown of Rab5 signaling protein in endothelial cells resulted in impaired microparticle uptake as compared with nonsense siRNA-treated cells, as well as an attenuation of the inflammatory response to microparticle treatment. Taken together, these data suggest that endocytosis of RBC-derived microparticles by lung endothelial cells results in endothelial cell activation. This response seems to be mediated, in part, by the Rab5 signaling protein.
INTRODUCTION
Hemorrhagic shock is a leading cause of death after traumatic injury (1) . Severe blood loss is frequently complicated by coagulopathy and organ failure (2) , and the transfusion of blood and blood products is a life-saving treatment in this patient population. Blood transfusion is not a harmless intervention, however, and exposes its recipients to the risk of transfusionrelated complications. Immunologic properties of the donor blood have been implicated in a myriad of adverse reactions, including fever, hemolysis, allergy, anaphylaxis, and lung injury (3, 4) . Recent studies have also identified the age of transfused packed red blood cell (pRBC) units as an independent risk factor for mortality among critically ill patients, suggesting that components of the aged erythrocyte may also be harmful to the recipient (5-7). The mechanisms by which these components interact with the transfusion recipient to cause harm, however, remain poorly understood.
Current US FDA regulations allow pRBC units to be stored up to 42 days after donation (8) . During this storage period, aging pRBC units accumulate metabolic, biochemical, and structural changes, collectively termed the erythrocyte storage lesion (9) . One characteristic feature of the storage lesion is the shedding of microparticles (MP) from aged RBCs. Previous work from our and other laboratories has demonstrated that RBC-derived MPs induce inflammatory changes during simulated massive transfusion in a small animal model, including pulmonary leukocyte sequestration, neutrophil activation, and acute lung injury (10, 11) . Although the pathophysiologic effects of RBC-derived MPs on the recipient have been well described in an animal model, the mechanisms underlying these changes are unknown. An understanding of these mechanisms may provide insight into the harmful effects of aged pRBC units on the transfusion recipient in the clinical setting.
In the present study, we hypothesized that MPs derived from stored pRBC units interact with endothelial cells through endocytosis, leading to a dysregulated activation response. Our data indicate that pulmonary endothelial cells endocytose MPs and traffic these vesicles to endothelial lysosomes. These cells become activated in response to MP exposure, generating a local proinflammatory milieu. Finally, we demonstrate that both MP endocytosis and MP-induced endothelial cell activation are mediated by the Rab5 signaling protein.
MATERIALS AND METHODS

Animal model
Male C57BL/6 mice aged 8 to 10 weeks were purchased from Jackson Laboratories (Bar Harbor, Maine). All mice were fed a standard laboratory diet and water ad libitum. Before experimentation, mice were acclimated to a 12-h light-dark cycle for 1 week and weighed 21 to 30 g. All experiments were approved by the Institutional Animal Care and Use Committee at the University of Cincinnati, and performed in accordance with their regulations.
Microparticle isolation protocol
Murine packed RBC units were collected using previously described methods (12) . Briefly, male C57BL/6 mice were anesthetized with 0.1 mg/g body weight intraperitoneal pentobarbital. Fresh whole blood was harvested through open cardiac puncture, and anticoagulated using citrate phosphate double dextrose (CP2D) solution in a 1:7 ratio. Anticoagulated whole blood was then centrifuged to separate the RBC pellet from the leukocyte-rich buffy coat and platelet-rich plasma, which were removed. This leukoreduced, plateletreduced RBC was resuspended in standard erythrocyte storage medium (additive solution-3) in a 2:9 ratio, and stored in light-protected conditions at 48C. As current FDA regulations limit human RBC storage at 42 days in humans (8) , and previous studies have demonstrated that murine blood accumulates metabolic and structural changes at 3 times the rate of human blood, our murine RBC was stored for a 14-day period (12) . After the storage period, MPs were isolated from the stored RBC via serial centrifugation. Specifically, the aged RBCs were centrifuged at 2,000 g for 10 min to remove the cellular fraction, and the supernatant fluid was collected. This supernatant was centrifuged at 10,000 g for 10 min and again the supernatant fluid was collected. This was centrifuged at 20,000 g for 30 min to isolate the MP pellet. The isolated MPs were then resuspended in either cell culture medium for in vitro experiments, or isotonic phosphate-buffered saline solution (PBS) for in vivo experiments. Previous experiments using flow cytometry have confirmed that MPs isolated using this protocol are predominantly RBC-derived (10, 11) .
Endothelial cell model
Primary murine lung microvascular endothelial cells (MLECs; Cell Biologics, Chicago, Ill) isolated from pathogen-free C57BL/6 mouse lung tissue were plated and grown to confluence in Dulbecco's Modified Eagle Medium (DMEM), supplemented with 10% fetal bovine serum. Cells were cultured in Nunclon Delta Surface 24-well plates (Thermo Scientific, Waltham, Mass). The culture area was 1.8 cm 2 and working volume was 1 mL. Glass slides were placed in wells and coated with 0.1% Gelatin Solution (ATCC) before seeding. MLECs were stored under sterile conditions at 378C and served as our in vitro model for endothelial cells. All cells were grown to confluent monolayers before experimentation.
Endothelial cell analysis
Confluent monolayers of MLECs were treated with MPs derived from 1 mL of murine blood, using cell culture media as a negative control. Our murine blood banking protocol yields approximately 10.7 AE 1.1 Â 10 6 MPs per 1 mL of murine pRBCs (data under review), whereas human pRBCs have been shown to shed significantly higher concentrations of MPs (11) . The concentration of MPs used in the present study, therefore, is relevant to the clinical setting. We simplified this ''dose'' of MPs to ''1 mL of murine blood'' as this represents the entire circulating volume of one mouse.
After a 6-h interval, cellular supernatant was removed for analysis. These samples were evaluated for interleukin-6 (IL-6) concentration using preadsorbed sandwich ELISA kits (Thermo Fisher Scientific, Waltham, Mass). Concurrently, treated MLECs were fixed with neutral-buffered formalin, and immunofluorescent staining was performed using antibodies for intercellular adhesion molecule (ICAM) and E-selectin (Abcam, Cambridge, Mass). Cells were counterstained with 4',6-diamidino-2-phenylindole dihydrochloride (DAPI). Leukocyte adhesion molecule expression was analyzed under confocal microscopy as previously described (10) . Briefly, eight random captures were taken of each slide using software ZEN 2012 version 1.1.2.0 on Axio Imager M2 microscope (Carl Zeiss AG, Jena, Germany). The fluorescent intensity of the adhesion molecule-specific subchannel was quantified using the imaging package ImageJ version 1.49v (Wayne Rasband, National Institutes of Health).
Microparticle endocytosis experiments
Before experimentation, erythrocyte-derived MPs were incubated with carboxyfluorescein succinimidyl ester (CFSE) at 378C. CFSE is a greenfluorescent probe that covalently binds amino acids and allows identification with immunofluorescence and flow cytometry (Sigma-Aldrich, St. Louis, Mo) (13) . CFSE-libeled MPs were washed with 1% bovine serum albumin to remove any unbound CFSE.
MLECs were treated with CFSE-labeled MPs and incubated at 378C for time intervals ranging from 15 min to 24 h. After the incubation period, MPs were removed from the cell culture supernatant and MLECs were resuspended in PBS. Cellular suspensions were analyzed for CFSE expression using fluorescence-activated cell sorting (FACS) analysis. In separate experiments, MLEC suspensions were treated with 0.4% trypan blue solution before FACS analysis, to quench nonendocytosed fluorescence (14) . The degree of MP endocytosis was quantified through the median fluorescence intensity (MFI) of treated cells.
All FACS experiments were repeated using pharmacological inhibitors of endocytosis. Confluent layers of MLECs were treated with inhibitors as indicated in the results section, incubated for 30 min, then treated with CFSE-labeled MPs for 1 h. After removing the MP-rich supernatant and washing the cells, MLECs were then resuspended in PBS, treated with trypan blue, and analyzed for green fluorescence through flow cytometry. Endocytosis inhibitors used include hypertonic sucrose (0.5 M), chloroquine (CQ), methylb-cyclodextrin (MBC), phenylarsine oxide (PAO), and Ly294002.
Lysosomal colocalization assay
MLECs were plated and grown to confluent monolayers in endothelial cell medium supplemented with 10% fetal bovine serum. Confluent layers of MLECs were treated with CFSE-labeled MPs derived from 1 mL of murine RBCs. After incubation periods of 2, 4, 8, 24, or 48 h, the MP-treated MLECs were fixed with neutral-buffered formalin. Lysosomal proteins were stained using CytoPainter Lysosomal Staining Kit (Abcam, Cambridge, Mass). Colocalization of lysosomes and CFSE-labeled MPs was determined via confocal microscopy.
Rab5 analysis
Confluent monolayers of MLECs were treated with small interfering ribonucleic acid (siRNA) specific for Rab5 GTPase for 48 to 72 h per manufacturer protocol (Santa Cruz Biotechnology, Dallas, Tex). Three separate Rab5-specific oligonucleotide sequences (Integrated DNATechnologies, Coralville, Iowa) were tested: 13.1 (5'-GUAGAAUCAAGUUUCUAAUUCUGAA-3'), 13.2 (5'-UCAAAGGCAAGCAAGUCCUAAUATT-3'), and 13.3 (5'-AAAUUUGGACAUGGCUAAUCGAGGA-3'). The nonsense (NS) siRNA control duplex sequence was used as control. As reported by the manufacturer (Integrated DNA Technologies), its genetic sequence is as follows: 5'-CGUUAAUCGCGUAUAAUACGCGUATAUACGCGUAUUAUACGC-GAUUAACGAC-3'.
Transfection was carried out per manufacturer recommendations. Briefly, cells were grown to 60% confluence at time of transfection. Lipofectamine RNAiMAX Reagent (3 mL) was used as the transfection reagent and diluted in Opti-MEM Medium (50 mL) per manufacturer instructions. A separate vial of Opti-MEM Medium (50 mL) was used to dilute the appropriate siRNA to 10 pmol concentration. Diluted siRNA was then added to diluted Lipofectamine reagent, and incubated for 5 min. This siRNA-lipid complex was added to cells and incubated for 2 to 3 days at 378C. The transfection efficiency of all sequences was compared with NS siRNA-treated cells using Western blot assay.
Rab5-knockdown experiments
After incubating confluent monolayers of MLECs with Rab5 or NS siRNA, cells were treated with CFSE-labeled MPs and flow cytometry experiments were performed as previously described. The degree of MP endocytosis was again quantified through MFI. In separate experiments, Rab5-knockdown (KD) cells were treated with RBC-derived MPs and incubated for 6 h. Cellular ICAM and E-selectin expression was determined via immunofluorescent assay, and IL-6 secretion was measured using ELISA kits as described above.
Statistical analysis
Results are reported as the mean and standard deviation where applicable. All experiments were performed in quadruplicate to ensure veracity of findings. Student t test was used to compare groups. Statistical analysis was performed After an incubation period of 6 h, endothelial cells treated with RBC-derived MPs demonstrated increased expression of the cell adhesion molecules ICAM (26.0 AE 12.0% increase) and E-selectin (20.3 AE 3.2% increase) as compared with vehicle ( Fig. 1, A and B) . IL-6 levels in the media were also higher in cells treated with MPs as compared with vehicle (171.0 AE 59.0% increase, Fig. 1C ). Taken together, these data confirm our recent work indicating that treatment of endothelial cells with MPs from stored RBC units leads to endothelial cell activation (10) .
Microparticles are endocytosed by endothelial cells
The mechanism by which erythrocyte-derived MPs activate endothelial cells is unknown. Previous studies have suggested that MPs derived from other cell types, such as platelets and endothelial cells, may activate endothelial cells via endocytosis (15, 16) (208.9 AE 6.3k MFI), and 24 h (147.8 AE 20.6k MFI) of incubation (Fig. 2 , B and C; each P < 0.05 vs. control). These data demonstrate that the increased endothelial cell fluorescence is predominantly intracellular in location, indicating that MPs undergo endocytosis by endothelial cells.
To determine the intracellular destination for MPs after endocytosis, MLECs treated with CFSE-labeled MPs were analyzed using confocal microscopy. We found that there was an increase in intracellular CFSE within endothelial cells in a time-dependent manner. After staining for lysosomal proteins, CFSElabeled MPs colocalized with lysosomes within the murine lung endothelial cells, indicating endolysosomal trafficking of endocytosed MPs (Fig. 3) . Taken together, these data indicate that MPs from stored pRBC units undergo endocytosis by endothelial cells and are subsequently trafficked to lysosomal vesicles.
In additional experiments, we used endocytosis inhibitors to attempt to inhibit uptake of RBC-derived MPs by endothelial cells. Five inhibitors were investigated. Hypertonic sucrose (0.5 M) targets clathrin-mediated endocytosis (CME) by trapping clathrin mobility (18) . CQ affects CME by altering the function of clathrin-coated vehicles (19) . The mechanism of PAO is less clear, but has also been shown to block CME (20) . MBC sequesters cholesterol from the cellular membrane, affecting lipid raft mobility (21) . Finally, Ly294002 is a specific inhibitor of phosphatidylinositol-3-kinase, and blocks both endocytosis and intracellular vesicle transport (22) .
Endothelial cells exposed to CFSE-labeled MPs without any inhibitor served as positive controls. Cells were treated with MPs for 1 h before analysis. Among the positive controls, 55.7 AE 2.1% of treated cells exhibited intracellular fluorescence. Each inhibitor impaired MP endocytosis to varying degrees (Fig. 4) , including hypertonic sucrose (16.0 AE 3.2% of total cells), CQ (22.2 AE 4.0%), PAO (22.4 AE 1.3%), MBC (39.3 AE 3.0%), and Ly294002 (22.1 AE 5.6%; each P < 0.05).
Microparticle endocytosis is mediated by Rab5
Rab5 is a small GTPase that regulates endosomal biogenesis and fusion of endocytic vesicles to endosomes (23) (24) (25) (26) . Given the role of Rab5 in mediating endocytosis, we hypothesized that MP endocytosis is mediated by Rab5. MLECs were transfected with nonsense siRNA as a negative control or three different nucleic acid sequences of Rab5 siRNA (13.1, 13.2, 13.3). Western blot was then used to quantify Rab5 transfection efficiency (Fig. 5, A and B) . MLECs transfected with Rab5 siRNA demonstrated decreased protein expression with all three sequences. The greatest decrease was observed with the 13.1 sequence. The 13.1 sequence was therefore used in all subsequent experiments.
To determine the role of Rab5 in MP endocytosis by endothelial cells, confluent monolayers of MLECs were transfected with Rab5 or nonsense siRNA per manufacturer protocol. Cell populations were then treated with either vehicle or CFSElabeled MPs and analyzed via flow cytometry (Fig. 5, C 
Rab5 mediates microparticle-associated endothelial activation
In a final series of experiments, we investigated the role of Rab5 on endothelial cell activation after MP treatment. Nonsense siRNA-treated cells served as a negative control. Cells pretreated with Rab5 siRNA, then exposed to MPs, demonstrated decreased expression of ICAM, E-selectin, and IL-6 as compared with cells treated with nonsense siRNA, before MP exposure (Fig. 6) . Taken together, these results demonstrate that Rab5 plays a key role in endothelial activation by RBC-derived MPs.
DISCUSSION
In the present study, we investigated the mechanism by which RBC-derived MPs activate pulmonary endothelial cells. Our results demonstrate that MPs from aged pRBC units undergo endocytosis by lung endothelial cells and are trafficked to lysosomal vesicles. Both endocytosis and endothelial cell activation seem to be regulated by the Rab5 signaling protein, suggesting that these processes may be linked to a common pathway. Together, these data describe one mechanism by which components of aged blood interact with the transfusion recipient, and provide novel insight into the potential harms of stored blood.
Traumatic injury is a leading cause of death and disability worldwide, with uncontrolled hemorrhage accounting for over 30% of trauma-associated mortality (1, 27) . Although resuscitation strategies are an area of ongoing research, strategic transfusion of blood products remains the standard of care in this critically ill patient population (28, 29) . Blood transfusion is not without risk, however, and several studies have suggested that resuscitation with older blood products may harm the transfusion recipient. According to recent literature, critically ill and complex surgical patients seem to be most vulnerable to harm related to old blood (5, 30, 31) . Although the reasons for this are poorly understood, previous studies suggest that elements of the erythrocyte storage lesion may be accountable (32) . MPs are 0.1 to 1.0 mm vesicles shed from the aging RBCs as a key element of this storage lesion, and have been shown to inflict harm in animal models of transfusion (10, 11) . Even though over 20 million blood products are transfused each year in the United States (33), surprisingly little is known about how MPs from aged pRBCs affect the transfusion recipient.
Previous research from our and other laboratories have discovered several key characteristics regarding RBC-derived MPs. First, MPs accumulate within the pRBC unit as a function of storage duration. Aged murine and human pRBC units contain a substantially higher number of MPs as compared with freshly isolated pRBC units (11) . Second, the physiologic function of MPs is incompletely understood, but data suggest that these vesicles play a role in RBC self-preservation by selectively sequestering damaged proteins and lipids before shedding (34) . Third, removal of MPs before transfusion, either through cell washing or bioactive lipid modulation, attenuates the proinflammatory response in the transfusion recipient (35) . Fourth, as part of this proinflammatory response, RBC-derived MPs promote endothelial cell activation and transfusion-related lung injury in a murine model of transfusion (10, 11) .
Our findings elucidate one mechanism by which RBCderived MPs promote the dysregulated activation of endothelial cells. Endothelial activation is a well-defined process characterized by upregulation of leukocyte adhesion molecules (e.g., ICAM, E-selectin) and a proinflammatory response (e.g., IL-6) (36, 37) . Under normal physiologic conditions, these changes serve to promote leukocyte diapedesis and transmigration to the site of injury. Dysregulated endothelial activation, however, can lead to an exaggerated immunologic response and contribute to the pathogenesis of acute lung injury (10) . The current data confirm our previous findings of MP-induced endothelial activation, and provide strong evidence that endothelial cells endocytose RBC-derived MPs. These MP-laden endosomes seem to be trafficked to lysosomal vesicles after endocytosis. We also demonstrate that the Rab5 signaling protein mediates both processes, in part, suggesting that MP endocytosis and endothelial activation may share a common pathway.
Previous investigations from our laboratory have elucidated different cellular interactions by which pRBC-derived MPs may harm the transfusion recipient. As mentioned, MPs have been shown to activate lung endothelial cells after transfusion (38) . These activated endothelial cells upregulate their expression of adhesion molecules, which leads to the pulmonary sequestration of leukocytes (38) . MPs from pRBC units have also been shown to prime neutrophils, as evidenced by superoxide generation and increased surface expression of CD11b (11) . Together, these interactions contribute to the development of transfusion-associated lung inflammation and injury (11, 35) . Although previous efforts have focused on the removal of MPs to reduce this inflammatory response (35, 39) , in the present study, we provide further insight into the mechanisms by which pRBC-derived MPs harm the transfusion recipient. Future studies may consider the endocytic pathways of the host endothelium as potential targets for intervention.
Our findings must be considered in light of three limitations. The first limitation relates to the clinical relevance of RBCderived MPs. Although transfusion of MPs themselves have no clinical indication, these vesicles likely become relevant with larger volumes of blood transfusion. Previous studies have shown that the biological effects of MPs on the transfusion recipient are more pronounced with higher concentrations (11) , and the overall concentration of MPs present in human blood units far exceeds those isolated from our murine model (35) . Thus, patients receiving multiple units of aged packed RBCs are frequently exposed to large concentration of potentially harmful MPs. The second limitation is our exclusive use of a murine model. We used a small animal model due the variability of storage lesion development in humans. A recent publication describes aspects of the storage lesion, including MP formation, as being significantly affected by poorly understood characteristics of the pRBC unit donor (40) . Separate studies have demonstrated that different patients have different ''microvesicle phenotypes,'' which further introduces additional variables with the use of a human model (41) . In the present study, the use of genetically similar small animals maximizes our ability to investigate endocytosis without introducing additional variables into our experimental design. Our third limitation is the exclusion of female mice from our experiments. Previous studies have documented the impact of mouse sex on erythrocyte characteristics, including membrane integrity (42) , ability to resist mechanical stress (43) , and storage-related hemolysis (44) . Therefore, we focused on male mice intentionally, to decrease sex-related variability in the development of the storage lesion.
In conclusion, MPs are submicron vesicles shed from aging erythrocytes during the storage period. These MPs are endocytosed by lung endothelial cells in a Rab5-mediated mechanism and result in activation of endothelial cells. Blood transfusion is a common practice in modern medicine, and yet the manifold relationships between the transfused RBCs and the transfusion recipient are incompletely understood. Through our experiments on the impact of aged blood, future investigations may elucidate mechanisms and potential strategies for minimizing adverse effects in the transfusion-dependent patient.
